Evgen Pharma (GB:TCF) has released an update.
TheraCryf plc, formerly Evgen Pharma, reported a transformative year with a decreased post-tax loss and reduced cash outflow, alongside securing a grant for a glioblastoma clinical trial. The company observed promising activity of their lead drug SFX-01 in various cancer models and successfully acquired Chronos Therapeutics, expanding their neuropsychiatry portfolio. Despite a challenging market, TheraCryf is actively pursuing non-dilutive funding for their expanded pipeline and is progressing with the integration of Chronos Therapeutics.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.
